Faculty Disclosure

In accordance with the ACCME Standards for Commercial Support, course directors, planning committees, faculty and all others in control of the educational content of the CME activity must disclose all relevant financial relationships with any commercial interest that they or their spouse/partner may have had within the past 12 months. If an individual refuses to disclose relevant financial relationships, they will be disqualified from being a part of the planning and implementation of this CME activity. Owners and/or employees of a commercial interest with business lines or products relating to the content of the CME activity will not be permitted to participate in the planning or execution of any accredited activity.

Nature of Relevant Financial Relationship Last Name Commercial Interest What Was Received For What Role Ali  Amgen  Honorarium  Speakers Bureau

Andrey  None  N/A  N/A

Bhangoo  None  N/A  N/A

Bollin  None  N/A  N/A

Carey  Genentech, GlaxoSmithKline, Sanofi  Grants  Research Support  AbbVie Inc., AstraZeneca, Clovis Oncology, Esperance Pharmaceuticals, Inc., Gateway Foundation Genentech/Roche, Janssen Biotech Inc., Merck, V Foundation for Cancer  Grants  Clinical Trail Research  Honorarium, Travel  Advisory Board Coleman Expenses  Co‐Director of GOG  Abbvie Inc., AstraZenca, Bayer  Stipend Partners HealthCare Pharmaceuticals, Clovis Oncology, Esperance Pharmaceuticals, Genentech/Roche, Janssen Biotech Inc., Merck  GOG‐Foundation ‐ NRG Costantini  None  N/A  N/A  AbbVie Inc., Bayer, Bessor Pharmaceutical, Daiichi‐Sankyo, EMD‐ Serono, Erasca Pharmaceuticals. Epizyme, Janssen, Loxo Oncology, Mirati Therapeutics, Novartis, Pfizer ,  Consulting Fees  Consultant PharmaMar, Polaris Pharmaceuticals, Demetri  Grants  Research Support Roche (acquired Ignyta), Sanofi, WIRB  Consulting Fees  Advisory Board Copernicus Group, ZioPharm  Adaptimmune, GlaxoSmithKline  Blueprint Medicines, Caris Life Sciences, Champions Oncology, G 1 Therapeutics, Merrimack Pharmaceuticals  Aspen Pharmacare, Boehringer  Honorarium/Consulti  Advisory Board Ingelheim, Laboratoires Servier ng Fees  Consultant  Janssen Biotech Inc., Sanofi  Consulting Fees Douketis  Speakers Bureau  Leo Pharma, Pfizer  Honorarium  Author/Editor  The Merck Manual, Up‐To‐Date  Royalties  CME Reviewer  Journal of Thrombosis and Haemostasis  Honorarium

Dyrbye  Communication Wiring Specialists, Inc.  Royalties  Co‐Inventor

 Alnylam Pharmaceuticals, Amgen, Prothena Corp, WebMD  Consultant  Amgen, Celgene, Janssen, Johnson &  Consulting Fees  Speaker Johnson, Medscape, Pharmacyclics,  Honorarium  Protocol Physicians Education Resource,  Honorarium Development Gertz Research to Practice  Grants  Advisory Board  Appellees, Annexon  Grants  Investigator  Janssen, Spectrum  Honorarium  Drug Safety  Amyloidosis Foundation, International Monitoring Board Waldenstrom Foundation  AbbVie Inc.  Consulting Fees,  Advisory Board,  Blueprint Medicines, Deciphera, Incyte, Gotlib Grants, Honorarium, Clinical Trail, Travel Novartis Research Support Expenses Graham  None  N/A  N/A

Gromes  BTG PLC  Consulting Fees  Consutlant

 Audro Biotech, Bristol‐Myers Squibb, Halozyme, Inc, Rafael Pharmaceuticals, Inc., Roche  Honorarium  Advisory Board Hecht  AbbVie Inc., Advaxis, Amgen, Forty  Grants  Research Support Seven Inc., Halozyme, Inc., Merck, Novartis

 Stock Opitons  Advisory Board  Caris Life Sciences  Salary  Advisory Board  Caris Life Sciences, WCG Oncology Heimberger  Royalty/Liscencing  Licensed Intellectual  Celldex Therapeutics Fees Property  Merck  Research Grant  Principle Investigator  AbbVie Inc., Adaptimmune, Array BioPharma, Apexigen, AstraZeneca, BerGenBio, Boehringer Ingelheim, Checkpoint Therapeutics, EMD Serono, Genentech/Roche, Genmab, G1 Therapeutics, Dynavax, Hengrui  Research Grant Therapeutics, Janssen, Lilly, Lycera,  Grants  Consultant/Advisory Johnson Merck, Daiichi, Mirati Therapeutics,  Honorarium Board Neovia, Novartis, Pfizer, Regeneron,  Fees  Contract Lobbyist Sanofi, Sanky, Stemcentrix, Syndax, (Spouse) Tarveda  Celgene, Boehringer Ingelheim, Genentech/Roche, LOXO, Mirati, Sanofi  Astellas, Otsuka Pharmaceuticals (Spouse)  AbbVie Inc., Agios Amgen, Ariad, Astex, Bristol‐Myers Squibb, Cyclacel, Daiichi‐ Sankyo, Immunogen, Jazz, Novartis,  Research Grants  Research Kantarjain Pfizer,  Honorarium  Speakers Bureau  AbbVie, Actinium, Agios Amgen, Immunoggen, Orsinex, Pfizer, Takeda Kelton  None  N/A  N/A

 Amgen, EMD Serono Inc., Genentech,  Grants  Research Support Kosty Merck & Co.  Consulting Fees  Consultant  Biocept Inc. Lin  None  N/A  N/A

Lopez  None  N/A  N/A  CSL Behring, HEMA Biologics, Novo  Honorarium  Advisory Board Nordisk, Shire Ma  Research Funding  Principle Investigator  Shire  Consulting Fees  Consulting  Accordant  Genentech, Gilead/Kite, Oncopeptides,  Honorarium  Advisory Board Mahindra  Amgen, Janssen, Sanofi  Honorarium  Speakers Bureau Moll  Janssen, Diagnostica Stago, Grifols  Honorarium  Consultant  Astellas, AstraZeneca, Sanofi  Consulting Fees  Consultant Morgans  Astellas, AstraZeneca, Sanofi, Janssen,  Honorarium  Advisory Board Bayer, Genentech  AbbVie Inc., Arog Astellas, Diiachi Sankyo,  Consulting/  Consulting Fees Perl  AbbVie Inc., Agios, Arog, Astellas, Committees  Honorarium Diiachi Jass Pharmaceuticals, New Link  Advisory Board Genetics, Novartis, Sankyo, Takeda Prasad  None  N/A  N/A

Reeves  Incyte  Honorarium  Advisory Board

Samuelson‐Bannow  None  N/A  N/A

 Amgen, Astra Zeneca, Celgene, Gilead Sciences, Incyte, Takeda  Speaker & Advisory Saven  Honorarium Oncology,AbbVie, Pharmacyclics, Board Seattle Genetics Shpall  None  N/A  N/A  Celgene  Honorarium  Speakers Bureau Sigal  Genentech, Molecular Response  Honorarium  Advisory Board Sinclair  None  N/A  N/A

Srinivas  None  N/A  N/A

Stanton  None  N/A  N/A  Bristol Meyers‐Squibb, Merck,  Research Grants  Investigator Svoboda Pharmacyclics, Seattle Genetics  Honorarium  Advisory Board  Kite, Kyown Kirin, Pharmacyclics Torrey  None  N/A  N/A

Towle  None  N/A  N/A

Vanbuskirk  None  N/A  N/A  WL Gore  Research Grants  Research Warkentin  Octapharma Bayer , WL Gore, Law firms  Consulting Fees  Consultant

 AbbVie Inc., Acerta Pharma, LLC, Cyclacel, Genentech, Gilead Sciences, Janssen, Juno Therapeutics, Weirda Karyopharm, KITE Pharma, Loxo  Grant Funding  Research Oncology, Miragen, Novartis, Oncternal Therapeutics, Pharmacyclics LLC., Sunesis, Xencor  Bristol‐Myers Squibb, Celgene, Westin Genentech, Gilead, Janssen, Merck,  Grant Funding  Research Novartis  AstraZeneca, Celgene, Genentech,  Advisory Xavier Gilead Sciences Inc., Incyte, Seattle  Honorarium Board/Speaker Genetics, Takeda CME Review  None  N/A  N/A Committee Scripps Conference  None  N/A  N/A Services & CME

Faculty Disclosure

Glossary of Terms

Commercial Interest The ACCME defines a “commercial interest” as any entity producing, marketing, re‐selling, or distributing health care goods or services, used on, or consumed by, patients. The ACCME does not consider providers of clinical service directly to patients to be commercial interests. For more information, visit www.accme.org.

Financial Relationships Financial relationships are those relationships in which the individual benefits by receiving a salary, royalty, intellectual property rights, consulting fee, honoraria, ownership interest (e.g., stocks, stock options or other ownership interest, excluding diversified mutual funds), or other financial benefit. Financial benefits are usually associated with roles such as employment, management position, independent contractor (including contracted research), consulting, speaking and teaching, membership on advisory committees or review panels, board membership, and other activities from which remuneration is received, or expected. ACCME considers relationships of the person involved in the CME activity to include financial relationships of a spouse or partner.

Relevant Financial Relationships ACCME focuses on financial relationships with commercial interests in the 12‐month period preceding the time that the individual is being asked to assume a role controlling content of the CME activity. ACCME has not set a minimal dollar amount for relationships to be significant. Inherent in any amount is the incentive to maintain or increase the value of the relationship. The ACCME defines “’relevant’ financial relationships” as financial relationships in any amount occurring within the past 12 months that create a conflict of interest.

Conflict of Interest Circumstances create a conflict of interest when an individual has an opportunity to affect CME content about products or services of a commercial interest with which he/she has a financial relationship.